Skip to main content
Header logo
  • Contact
  • Please fill out this field
  • Company Open link menu
    Company
    • About MEI Pharma
    • Management
    • Board of Directors
    • Our Mission and Commitment
    • Collaborations
  • Focus Open link menu
    Focus
    • Our Focus
    • Hematologic Malignancies
    • Solid Tumors
  • Pipeline Open link menu
    Pipeline
    • Programs
    • Pipeline Overview
    • Voruciclib
    • ME-344
    • More Information
    • Clinical Trials
    • Collaborations
    • Publications
  • Patients Open link menu
    Patients
    • Patients & Caregivers Overview
    • Clinical Trials
  • Investors Open link menu
    Investors
    • Investor Overview
    • Investor Summary
    • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Reports
    Investors
    • Events & Presentations
    • Events Calendar
    • Presentations
    • Stock Information
    • Analyst Coverage
    • Stock Quote & Chart
    • Historical Stock Lookup
    Investors
    • Corporate Governance
    • Governance Documents
    • Board of Directors
    • Committee Composition
    • Environment, Social, and Governance
    • Investor Resources
    • Email Alerts
    • Contact IR
  • News & Media Open link menu
    News & Media
    • Press Releases
  • Careers
Please fill out this field
Press Releases

Press Releases

Breadcrumbs

  • Home
  • News & Media
  • Press Releases
2023 2022 2021 2020 2019 2018 2017 2016 2015
More
Date Title Download
Oct 2 2023 MEI Pharma Adopts Limited-Duration Stockholder Rights Plan PDF
Sep 28 2023 MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions PDF
Sep 26 2023 MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights /sites/meipharma-corp/files/2023-09/meip-q4-2023fye-earnings-final.pdf
Sep 21 2023 MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023 PDF
Sep 18 2023 MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car PDF
Aug 16 2023 MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer PDF
Jul 23 2023 MEI Pharma Announces Results of Special Meeting of Stockholders PDF
Jul 19 2023 MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction PDF
Jul 18 2023 MEI Pharma Responds to Anson and Cable Car PDF
Jul 17 2023 MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 6 2022 MEI Pharma Announces Adjournment of Annual Meeting of Stockholders PDF
Dec 5 2022 MEI Pharma Initiates Strategic Realignment PDF
Dec 5 2022 MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting PDF
Nov 18 2022 Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan PDF
Nov 14 2022 MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights /sites/meipharma-corp/files/2022-11/meip-q1-2023-fiscal-earnings-final.pdf
Nov 3 2022 MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022 PDF
Oct 3 2022 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Sep 22 2022 MEI Pharma Announces Changes to Board of Directors PDF
Sep 8 2022 MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights /sites/meipharma-corp/files/2022-09/meip-2022-earnings-release-final.pdf
Sep 6 2022 MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 6 2021 MEI Pharma Announces Closing of Public Offering of Common Stock PDF
Dec 3 2021 MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PDF
Dec 1 2021 MEI Pharma Announces Pricing of Public Offering of Common Stock PDF
Nov 30 2021 MEI Pharma Announces Proposed Public Offering of Common Stock PDF
Nov 23 2021 MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors PDF
Nov 10 2021 MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights /sites/meipharma-corp/files/meip-q1-2022-fiscal-earnings.pdf
Nov 10 2021 MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma /sites/meipharma-corp/files/pr-11-10-2021.pdf
Nov 4 2021 MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting /sites/meipharma-corp/files/pr-11-04-2021.pdf
Nov 1 2021 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Oct 1 2021 MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Nov 10 2020 MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights PDF
Nov 9 2020 MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences PDF
Oct 2 2020 Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma PDF
Sep 15 2020 MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing PDF
Sep 9 2020 MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights PDF
Sep 4 2020 MEI Pharma to Present at Upcoming Investor Conferences in September PDF
Sep 2 2020 MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020 PDF
Aug 4 2020 MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020 PDF
Jul 2 2020 Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis PDF
May 27 2020 MEI Pharma to Present at the Jefferies Virtual Healthcare Conference PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 19 2019 MEI Pharma Announces Closing of Public Offering of Common Stock PDF
Dec 17 2019 MEI Pharma Announces Pricing of Public Offering of Common Stock PDF
Dec 16 2019 MEI Pharma Announces Proposed Public Offering of Common Stock PDF
Nov 12 2019 MEI Pharma to Present at the Stifel 2019 Healthcare Conference PDF
Nov 7 2019 MEI Pharma Reports First Quarter Fiscal Year 2020 Results and Operational Highlights PDF
Oct 3 2019 MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies PDF
Sep 23 2019 MEI Pharma to Host Investor and Analyst Event on October 4, 2019 PDF
Aug 29 2019 MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference PDF
Aug 28 2019 MEI Pharma Reports Fiscal Year 2019 Results and Operational Highlights PDF
Aug 21 2019 MEI Pharma to Release 2019 Fiscal Year End Financial Results and Provide Corporate Update on August 28, 2019 PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 3 2018 Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting PDF
Dec 2 2018 MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting PDF
Dec 1 2018 MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting PDF
Nov 8 2018 MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights PDF
Nov 6 2018 MEI Pharma To Present at Stifel 2018 Healthcare Conference PDF
Nov 5 2018 MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan PDF
Nov 1 2018 MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting PDF
Oct 11 2018 MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies PDF
Aug 30 2018 MEI Pharma Reports Fiscal Year 2018 Results and Operational Highlights PDF
Aug 29 2018 MEI Pharma To Present at Wells Fargo Securities 2018 Healthcare Conference PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 21 2017 MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports PDF
Nov 22 2017 MEI Pharma to Host Annual Meeting of Stockholders PDF
Nov 8 2017 MEI Pharma Reports First Quarter Fiscal Year 2018 Results PDF
Nov 7 2017 MEI Pharma to Present at Stifel 2017 Healthcare Conference PDF
Sep 19 2017 MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference PDF
Sep 5 2017 MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor PDF
Sep 5 2017 MEI Pharma Reports Fiscal Year 2017 Results PDF
Aug 31 2017 MEI Pharma to Present at Two Upcoming Investor Conferences PDF
Aug 29 2017 MEI Pharma to Host Fiscal Year End Conference Call on September 5, 2017 PDF
Aug 2 2017 Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 5 2016 Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia PDF
Nov 17 2016 MEI Pharma to Host Annual Meeting of Stockholders PDF
Nov 9 2016 MEI Pharma Reports First Quarter Fiscal Year 2017 Results PDF
Nov 7 2016 MEI Pharma to Present at Stifel Healthcare Conference PDF
Nov 3 2016 Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting PDF
Sep 6 2016 MEI Pharma Reports Fiscal Year 2016 Results PDF
Aug 10 2016 MEI Pharma to Present at Wedbush PacGrow Healthcare Conference PDF
Aug 8 2016 Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases PDF
Aug 1 2016 MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy PDF
Apr 20 2016 MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page
Date Title Download
Dec 10 2015 MEI Pharma Appoints Dr. Christine White as Chairman of the Board PDF
Dec 7 2015 MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study PDF
Nov 23 2015 MEI Pharma to Host Annual Meeting of Stockholders PDF
Nov 11 2015 MEI Pharma to Present at Stifel Healthcare Conference PDF
Nov 5 2015 MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome PDF
Oct 19 2015 MEI Pharma to Present at 14th Annual BIO Investor Forum PDF
Oct 6 2015 MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting PDF
Sep 2 2015 MEI Pharma Reports Fiscal Year 2015 Results PDF
Aug 4 2015 MEI Pharma to Present at Wedbush PacGrow Healthcare Conference PDF
Jul 1 2015 MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference PDF

Pagination

  • Current page 1
  • Page 2
  • Next page
  • Last page

Connect with Us.

© MEI Pharma, Inc.
11455 El Camino Real, Suite 250
San Diego, CA 92130
Keep up to date on social media

Footer

  • Site Map
  • Privacy Notice
  • Terms of Use
  • Cookies Policy
  • Contact
  • Cookie Settings
  • Copyright 2023
DOCPDFPDFXBRLXLS